CA Intermediate · Advanced Accounting · AS 12 Accounting for Government Grants
Anand Foods Ltd. received ₹5,00,000 from the government as an immediate financial support to compensate for losses already incurred in 2024-25, with no future related costs. The grant was received in 2025-26. Which treatment is correct under AS 12?
The grant is recognised as income in the period it becomes receivable, 2025-26, with suitable disclosure and extraordinary-item presentation if warranted. AS 12 treats grants compensating for losses already incurred or giving immediate support with no future costs as immediate income, not deferred.
- ACredit to capital reserve
- BRecognise as income in 2025-26 and disclose it, possibly as an extraordinary item if circumstances warrantCorrect
- CRecognise as deferred income over 5 years
- DDeduct from fixed assets
Explanation
A grant receivable as compensation for expenses or losses already incurred, or for immediate support with no future related costs, is recognised as income of the period in which it becomes receivable, with disclosure (extraordinary item if appropriate). Deferral applies only where there are related future costs.
Did you get it right without looking?
One question tells you little. A timed set on AS 12 Accounting for Government Grants shows your real accuracy, how long you take and where you lose marks.
More AS 12 Accounting for Government Grants questions
- Kaveri Industries Ltd purchased machinery on 1 April 2024 for ₹50,00,000 and received a government grant of ₹10,00,000 related to this speci…
- Narmada Pharma Ltd received on 1 April 2024 a grant of ₹30,00,000 for setting up a plant costing ₹1,20,00,000. It shows the grant as deferre…
- Kaveri Engineering Ltd bought machinery on 1 April 2025 for Rs 50,00,000. The government granted Rs 10,00,000 towards it, and the company ch…
- Sagar Textiles Ltd received a government grant of Rs 40 lakh in April 2025 as a compensation for losses already incurred in the previous yea…
- Kaveri Engineering Ltd purchased machinery on 1 April 2024 for ₹50,00,000 with a useful life of 10 years and no residual value (straight-lin…
- Narmada Pharma Ltd purchased a machine on 1 April 2025 for Rs 60,00,000 with a 6-year life and nil residual value (straight-line). It receiv…